← All trials
NCT06104306
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 13, 2023
- Primary completion
- Nov 30, 2024
- Completion date
- May 31, 2025
- First posted
- Oct 27, 2023
- Last posted
- Dec 26, 2023
- Enrollment
- 35
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Gilead SciencesLead sponsor
- Gilead SciencesStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.